A randomized, parallel group, placebo-controlled, double blind study to asses the safety and tolerability of SB 681323 at 7.5 mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatois arthritis”
Phase 1
- Conditions
- Rheumatoid Arthritis patients with CRP higher than 10 mg/
- Registration Number
- EUCTR2005-002219-26-HU
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To follow the serum CRP levels at the end of the trial;Secondary Objective: The follow the serum CRP levels during the trial<br>To follow clininal signs and <br>To follow safety and biomarkers ;Primary end point(s): The serum CRP level at the end of the trial
- Secondary Outcome Measures
Name Time Method